• Publications
  • Influence
Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury
Drug‐induced liver injury (DILI) is the most frequent reason cited for the withdrawal of approved drugs from the market and accounts for up to 15% of the cases of acute liver failure. InvestigatorsExpand
  • 487
  • 40
  • PDF
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.
The pregnane X receptor (PXR)/steroid and xenobiotic receptor (SXR) transcriptionally activates cytochrome P4503A4 (CYP3A4) when ligand activated by endobiotics and xenobiotics. We cloned the humanExpand
  • 281
  • 32
  • PDF
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
The increase in oral availability of felodipine and other commonly used medications when taken with grapefruit juice has been assumed to be due to inhibition of CYP3A4, a cytochrome P450 that isExpand
  • 621
  • 30
  • PDF
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
BACKGROUND & AIMS Idiosyncratic drug-induced liver injury (DILI) is among the most common causes of acute liver failure in the United States, accounting for approximately 13% of cases. A prospectiveExpand
  • 561
  • 22
  • PDF
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
The human colon carcinoma cell line, Caco-2, is widely used as a model for oral absorption of xenobiotics. The usefulness of Caco-2 cells has been limited, however, because they do not expressExpand
  • 321
  • 22
  • PDF
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
BACKGROUND & AIMS The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the firstExpand
  • 337
  • 22
  • PDF
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Enzymes within the P450IIIA (CYP3A) subfamily appear to account for significant "first pass" metabolism of some drugs in the intestine. To identify which of the known P450IIIA genes are expressed inExpand
  • 540
  • 20
Hepatic dysfunction associated with troglitazone.
To the Editor: Troglitazone is a thiazolidine 2,4-dione derivative that represents a novel class of oral drugs for the treatment of diabetes. In clinical trials, including two published in this issueExpand
  • 423
  • 18
Noninvasive tests of CYP3A enzymes.
  • P. Watkins
  • Biology, Medicine
  • Pharmacogenetics
  • 1 August 1994
  • 404
  • 17
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
Marked interindividual variability in expression of CYP3A4 influences the disposition of many endo- and xenobiotics, including the metabolism of steroids, environmental toxins and therapeuticallyExpand
  • 284
  • 15